BioCentury
ARTICLE | Finance

3Q Financial Markets Preview: Avoiding burnout

Assessing whether biotech stocks can continue to outperform the markets in 2H12

July 2, 2012 7:00 AM UTC

A slew of milestones through year end combined with last quarter's outperformance have investors hopeful that the biotech sector can continue to fend off a dreary macroeconomic environment and weakness in the broader markets.

Buysiders don't expect to see anything catch the imagination of investors and strategic acquirers quite the way HCV has in the last year. But they think positive Alzheimer's Phase III data, as well as another obesity approval, could continue to generate excitement within the sector...